切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2021, Vol. 10 ›› Issue (04) : 365 -370. doi: 10.3877/cma.j.issn.2095-3232.2021.04.006

临床研究

肝癌术后复发补救性肝移植疗效及预后影响因素
陈拓1, 张全保1, 陶一峰1, 沈丛欢1, 李瑞东1, 马震宇1, 李建华1, 陆录1, 陈进宏1, 钦伦秀1, 王正昕1,†()   
  1. 1. 200040　上海，复旦大学附属华山医院普通外科　复旦大学器官移植研究所
  • 收稿日期:2021-04-27 出版日期:2021-08-18
  • 通信作者: 王正昕
  • 基金资助:
    国家科技重大专项(2017ZX10203205); 国家自然科学基金面上项目(81773089，81873874); 上海申康医院发展中心临床三年行动计划(SHDC2020CR2021B)

Clinical efficacy and prognostic factors of salvage liver transplantation for postoperative recurrence of primary liver cancer

Tuo Chen1, Quanbao Zhang1, Yifeng Tao1, Conghuan Shen1, Ruidong Li1, Zhenyu Ma1, Jianhua Li1, Lu Lu1, Jinhong Chen1, Lunxiu Qin1, Zhengxin Wang1,†()   

  1. 1. Department of General Surgery, Huashan Hospital Affiliated to Fudan University, Institute of Organ Transplantation, Fudan University, Shanghai 200040, China
  • Received:2021-04-27 Published:2021-08-18
  • Corresponding author: Zhengxin Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

陈拓, 张全保, 陶一峰, 沈丛欢, 李瑞东, 马震宇, 李建华, 陆录, 陈进宏, 钦伦秀, 王正昕. 肝癌术后复发补救性肝移植疗效及预后影响因素[J]. 中华肝脏外科手术学电子杂志, 2021, 10(04): 365-370.

Tuo Chen, Quanbao Zhang, Yifeng Tao, Conghuan Shen, Ruidong Li, Zhenyu Ma, Jianhua Li, Lu Lu, Jinhong Chen, Lunxiu Qin, Zhengxin Wang. Clinical efficacy and prognostic factors of salvage liver transplantation for postoperative recurrence of primary liver cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(04): 365-370.

目的

探讨原发性肝癌（肝癌）术后复发补救性肝移植（SLT）疗效及预后影响因素。

方法

回顾性分析2014年5月至2019年10月在复旦大学附属华山医院行肝移植的273例肝癌患者临床资料。患者均签署知情同意书，符合医学伦理学规定。其中男252例，女21例；平均年龄（51±9）岁。根据术式不同分组，行初始肝移植（PLT）196例（PLT组），肝癌根治性切除后复发行SLT 77例（SLT组）。比较两组围手术期和并发症发生情况。生存分析采用Kaplan-Meier法和Log-rank检验。采用Cox比例风险回归模型分析SLT患者术后预后的独立影响因素。

结果

患者一般资料按1∶1倾向性评分匹配后，两组各70例。SLT组手术时间（479±106）min，明显长于PLT组的（438±79） min（t=2.587，P<0.05）；SLT组和PLT组围手术期死亡率分别为11%（8/70）、6%（4/70），差异无统计学意义（χ2=1.458，P>0.05）。SLT组术后1、3、5年总体生存率分别为85.7%、75.0%、63.3%，PLT组相应为88.3%、79.0%、70.3%；SLT组术后1、3、5年无瘤生存率分别为98.4%、72.2%、57.1%，PLT组相应为92.5%、74.3%、54.7%；两组总体生存和无瘤生存差异无统计学意义（χ2=1.627，0.265；P>0.05）。多因素分析显示，AFP>200 μg/L和肿瘤最大径>3 cm是SLT患者术后总体生存的独立危险因素（HR=2.630，3.082；P<0.05），亦是术后无瘤生存的独立危险因素（HR=5.965，3.166；P<0.05）。

结论

SLT是肝癌术后复发的一种安全可靠治疗手段，可获得与PLT相似的治疗效果。AFP和肿瘤直径为SLT患者术后预后的独立影响因素。

关键词: 肝肿瘤, 肝移植, 治疗结果, 危险因素
Objective

To evaluate the clinical efficacy and to explore the prognostic factors of salvage liver transplantation (SLT) for postoperative recurrence of primary liver cancer.

Methods

Clinical data of 273 patients with primary liver cancer who underwent liver transplantation in Huashan Hospital Affiliated to Fudan University from May 2014 to October 2019 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 252 patients were male and 21 female, aged (51±9) years on average. According to different surgical methods, 196 patients undergoing primary liver transplantation were assigned into the PLT group and 77 patients receiving SLT due to postoperative recurrence after radical resection were allocated into the SLT group. The perioperative conditions and incidence of complications were statistically compared between two groups. Survival analysis was performed by Kaplan-Meier method and Log-rank test. The independent influencing factors of postoperative prognosis of SLT patients were analyzed by Cox proportional hazards regression model.

Results

After propensity score matching of baseline data at a ratio of 1:1, 70 patients were assigned into each group. In the SLT group, the operation time was (479±106) min, significantly longer than (438±79) min in the PLT group (t=2.587, P<0.05). The perioperative mortality rate in the SLT group was 11%(8/70), which did not significantly differ from 6%(4/70) in the PLT group (χ2=1.458, P>0.05). The 1-, 3-, 5-year overall survival rates were 85.7%, 75.0%, 63.3% in the SLT group and were 88.3%, 79.0%, 70.3% in the PLT group, respectively. The 1-, 3-, 5-year tumor-free survival rates were 98.4%, 72.2%, 57.1% in the SLT group, and were 92.5%, 74.3%, 54.7% in the PLT group, respectively. The overall survival and tumor-free survival rates did not significantly differ between two groups (χ2=1.627, 0.265; P>0.05). Multivariate analysis demonstrated that AFP >200 μg/L and the maximal tumor diameter >3 cm were the independent risk factors for postoperative overall survival of SLT patients (HR=2.630, 3.082; P<0.05), which were also the independent risk factors for postoperative tumor-free survival (HR=5.965, 3.166; P<0.05).

Conclusions

SLT is a safe and reliable treatment for postoperative recurrence of primary liver cancer, which can yield equivalent clinical efficacy to PLT. AFP and tumor diameter are the independent risk factors for the postoperative prognosis of SLT patients.

Key words: Liver neoplasms, Liver transplantation, Treatment outcome, Risk factors
表1 PSM前后PLT组和SLT组肝癌患者一般资料比较
参数 PSM前 PSM后
PLT组 SLT组 统计值 P值 PLT组 SLT组 统计值 P值
性别（例，男/女） 183/13 69/8 χ2=1.099 0.295 63/7 64/6 χ2=0.085 0.771
年龄（岁，±s） 51±9 50±9 t=0.924 0.357 52±9 51±9 t=0.181 0.857
BMI（kg/m2，±s） 24±4 24±5 t=-0.155 0.877 24±5 25±5 t=-0.424 0.672
MELD评分（分，±s） 32±12 29±11 t=2.259 0.025 29±10 29±11 t=-0.109 0.913
术前辅助治疗（例） 37 34 χ2=18.357 <0.001 28 27 χ2=0.030 0.863
AFP >200 μg/L（例） 70 19 χ2=3.066 0.080 17 19 χ2=0.150 0.699
乙型病毒性肝炎（例） 175 73 χ2=2.024 0.155 66 66 χ2=0 1.000
Child-Pugh分级（例）     χ2=4.405 0.111     χ2=1.234 0.540
  A级 15 11     6 7    
  B级 43 21     15 10    
  C级 138 45     49 53    
腹腔积液（例） 96 31 χ2=1.690 0.194 31 30 χ2=0.029 0.865
米兰标准（例） 81 25 χ2=1.827 0.177 24 23 χ2=0.032 0.858
UCSF标准（例） 95 33 χ2=0.699 0.403 33 30 χ2=0.260 0.610
杭州标准（例） 145 63 χ2=1.872 0.171 59 56 χ2=0.438 0.508
肿瘤数目（例）     χ2=6.511 0.039     χ2=4.500 0.105
  1个 108 32     40 31    
  1～3个 53 21     20 19    
  >3个 35 24     10 20    
微血管侵犯（例） 151 59 χ2=0.005 0.941 51 54 χ2=0.343 0.558
肿瘤最大径>3 cm（例） 113 37 χ2=2.059 0.151 43 35 χ2=1.853 0.173
肿瘤中低分化（例） 81 37 χ2=1.019 0.313 26 35 χ2=2.353 0.125
表2 PLT组和SLT组肝癌患者围手术期死亡和并发症比较（例）
组别 例数 围手术期死亡 感染 肾衰竭 急性排斥反应 胆道并发症 血管并发症 移植物丢失
SLT组 70 8 6 1 8 3 2 2
PLT组 70 4 4 0 10 9 3 2
χ2值   1.458 0.431 - 0.255 3.281 0 0
P值   0.227 0.512 1.000 0.614 0.070 1.000 1.000
图1 PSM后PLT组和SLT组肝癌患者术后生存的Kaplan-Meier生存曲线
表3 影响补救性肝移植肝癌患者预后的Cox多因素分析
参数 总体生存 无瘤生存
HR 95%CI P值 HR 95%CI P值
AFP>200 μg/L 2.630 1.122～6.166 0.026 5.965 2.397～14.844 <0.001
肿瘤最大径>3 cm 3.082 1.285～8.181 0.013 3.166 1.252～8.005 0.015
[1]
Majno PE, Sarasin FP, Mentha G, et al. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis[J]. Hepatology, 2000, 31(4):899-906.
[2]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3]
Fuks D, Dokmak S, Paradis V, et al. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis[J]. Hepatology, 2012, 55(1): 132-140.
[4]
Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence[J]. Ann Surg, 2003, 237(4):536-543.
[5]
Starzl TE. The long reach of liver transplantation[J]. Nat Med, 2012, 18(10):1489-1492.
[6]
陆才德，房炯泽. 肝癌肝移植研究进展[J]. 浙江医学, 2020, 42(14):1459-1463.
[7]
Laurent A, Tayar C, Andréoletti M, et al. Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 2009, 16(3):310-314.
[8]
Silva MF, Wigg AJ. Current controversies surrounding liver transplantation for hepatocellular carcinoma[J]. J Gastroen Hepatol, 2010, 25(7):1217-1226.
[9]
Adam R, Azoulay D, Castaing D, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?[J]. Ann Surg, 2003, 238(4):508-518.
[10]
何晓顺，巫林伟，郭志勇, 等. 挽救性肝移植治疗肝癌切除术后肿瘤复发[J]. 中华器官移植杂志, 2011, 32(6):343-346.
[11]
陈杰，许永华，李相成. 肝切除后再行肝移植与直接行肝移植治疗肝癌的比较[J]. 中华器官移植杂志, 2010, 31(1):18-20.
[12]
Huang ZY, Liang BY, Xiong M, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China[J]. Ann Surg Oncol, 2012, 19(8):2515-2525.
[13]
常虎林，许鑫森，曲凯, 等. 补救性肝移植对原发性肝癌肝切除术后复发患者的疗效分析[J]. 器官移植, 2014, 5(2):89-94.
[14]
Vennarecci G, Ettorre GM, Antonini M, et al. First-line liver resection and salvage liver transplantation are increasing therapeutic strategies for patients with hepatocellular carcinoma and child a cirrhosis[J]. Transplant Proc, 2007, 39(6):1857-1860.
[15]
Felli E, Cillo U, Pinna AD, et al. Salvage liver transplantation after laparoscopic resection for hepatocellular carcinoma: a multicenter experience[J]. Updates Surg, 2015, 67(2):215-222.
[16]
Kim S, Kim K, Ha T, et al. Salvage living donor liver transplantation for recurrent hepatocellular carcinoma after prior laparoscopic hepatectomy[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(5):473-476.
[17]
Levi Sandri GB, Lai Q, Ravaioli M, et al. The role of salvage transplantation in patients initially treated with open versus minimally invasive liver surgery: an intention-to-treat analysis[J]. Liver Transplant, 2020, 26(7):878-887.
[18]
Moon JI, Kwon CHD, Joh JW, et al. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival[J]. Transplant Proc, 2012, 44(2):487-493.
[19]
Wu L, Hu A, Tam N, et al. Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection[J]. PloS One, 2012, 7(7):e41820.
[20]
Shan Y, Huang L, Xia Q. Salvage liver transplantation leads to poorer outcome in hepatocellular carcinoma compared with primary liver transplantation[J]. Sci Rep, 2017(7):44652.
[21]
史瑞，张雅敏，许洋, 等. 直接肝移植与挽救性肝移植治疗原发性肝癌疗效分析[J]. 中华肝胆外科杂志, 2017, 23(2):87-89.
[22]
王洪良，董建辉，蓝柳根, 等. 补救性肝移植临床疗效的系统评价[J/CD]. 中华移植杂志(电子版), 2017, 11(3):177-183.
[23]
Bhangui P, Allard MA, Vibert E, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes?[J]. Ann Surg, 2016, 264(1):155-163.
[24]
Liang B, Huang Z, Zhou S, et al. Primary results of salvage liver transplantation in the patients with unresectable recurrent hepatocellular carcinoma after initial liver resection[J]. Hepatogastroenterology, 2014, 61(135):2014-2020.
[25]
Guerrini GP, Gerunda GE, Montalti R, et al. Results of salvage liver transplantation[J]. Liver Int, 2014, 34(6):e96-104.
[26]
Chan DL, Alzahrani NA, Morris DL, et al. Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma[J]. J Gastroen Hepatol, 2014, 29(1):31-41.
[27]
Zhu Y, Dong J, Wang WL, et al. Short- and long-term outcomes after salvage liver transplantation versus primary liver transplantation for hepatocellular carcinoma: a meta-analysis[J]. Transplant Proc, 2013, 45(9):3329-3342.
[28]
Guo Y, Tan EK, Krishnamoorthy TL, et al. Outcomes of salvage liver transplant for recurrent hepatocellular carcinoma: a comparison with primary liver transplant[J]. Ann Hepatobiliary Pancreat Surg, 2019, 23(1):1-7.
[29]
Xu X, Lu D, Ling Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6):1035-1041.
[30]
Mehta N, Dodge JL, Grab JD, et al. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time[J]. Hepatology, 2020, 71(3):943-954.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[2] 刘欢颜, 华扬, 贾凌云, 赵新宇, 刘蓓蓓. 颈内动脉闭塞病变管腔结构和血流动力学特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 809-815.
[3] 马艳波, 华扬, 刘桂梅, 孟秀峰, 崔立平. 中青年人颈动脉粥样硬化病变的相关危险因素分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 822-826.
[4] 陈旭渊, 罗仕云, 李文忠, 李毅. 腺源性肛瘘经手术治疗后创面愈合困难的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 82-85.
[5] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[6] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[7] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[8] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[9] 张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[10] 陆猛桂, 黄斌, 李秋林, 何媛梅. 蜂蛰伤患者发生多器官功能障碍综合征的危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1010-1015.
[11] 李达, 张大涯, 陈润祥, 张晓冬, 黄士美, 陈晨, 曾凡, 陈世锔, 白飞虎. 海南省东方市幽门螺杆菌感染现状的调查与相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 858-864.
[12] 李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[13] 孟科, 李燕, 闫婧爽, 闫斌. 胶囊内镜胃通过时间的影响因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 671-675.
[14] 杨艳丽, 陈昱, 赵若辰, 杜伟, 马海娟, 许珂, 张莉芸. 系统性红斑狼疮合并血流感染的危险因素及细菌学分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 694-699.
[15] 孙培培, 张二明, 时延伟, 赵春燕, 宋萍萍, 张硕, 张克, 周玉娇, 赵璨, 闫维, 吴蓉菊, 宋丽萍, 郭伟安, 马石头, 安欣华, 包曹歆, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病患病情况及相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 711-719.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号